Compare Stocks: AKBA, ANL, SANA, and LXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.58 +3.5%	$0.87	$0.54 ▼ $3.20	$161.28M	0.18	5.02 million shs	6.84 million shs
ANL Adlai Nortye	$10.49 -0.9%	$14.25	$0.88 ▼ $17.25	$675.23M	1.05	367,746 shs	36,954 shs
LXRX Lexicon Pharmaceuticals	$1.43 -4.4%	$1.99	$1.10 ▼ $2.68	$634.07M	1.07	2.91 million shs	1.10 million shs
SANA Sana Biotechnology	$2.32 -2.3%	$3.19	$2.22 ▼ $5.90	$696.01M	2.18	3.20 million shs	789,151 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-4.32%	-19.48%	-42.86%	-54.10%	-81.27%
ANL Adlai Nortye	-6.04%	-12.49%	-36.27%	-15.36%	+541.21%
LXRX Lexicon Pharmaceuticals	-4.49%	-9.70%	-31.65%	-34.93%	+7.19%
SANA Sana Biotechnology	+0.85%	-4.05%	-28.83%	-25.47%	-56.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.58 +3.5%	$0.87	$0.54 ▼ $3.20	$161.28M	0.18	5.02 million shs	6.84 million shs
ANL Adlai Nortye	$10.49 -0.9%	$14.25	$0.88 ▼ $17.25	$675.23M	1.05	367,746 shs	36,954 shs
LXRX Lexicon Pharmaceuticals	$1.43 -4.4%	$1.99	$1.10 ▼ $2.68	$634.07M	1.07	2.91 million shs	1.10 million shs
SANA Sana Biotechnology	$2.32 -2.3%	$3.19	$2.22 ▼ $5.90	$696.01M	2.18	3.20 million shs	789,151 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-4.32%	-19.48%	-42.86%	-54.10%	-81.27%
ANL Adlai Nortye	-6.04%	-12.49%	-36.27%	-15.36%	+541.21%
LXRX Lexicon Pharmaceuticals	-4.49%	-9.70%	-31.65%	-34.93%	+7.19%
SANA Sana Biotechnology	+0.85%	-4.05%	-28.83%	-25.47%	-56.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.43	Hold	$3.90	570.10% Upside
ANL Adlai Nortye	2.86	Moderate Buy	$29.50	181.35% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$5.70	300.00% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	303.17% Upside

Current Analyst Ratings Breakdown

Latest AKBA, ANL, SANA, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/21/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/12/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/5/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/28/2026	LXRX Lexicon Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$8.00
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$4.00
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$31.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$49.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$4.50

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	0.68	N/A	N/A	$0.12 per share	4.85
ANL Adlai Nortye	$5M	135.05	N/A	N/A	($0.21) per share	-49.93
LXRX Lexicon Pharmaceuticals	$49.80M	12.73	N/A	N/A	$0.30 per share	4.75
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest AKBA, ANL, SANA, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	AKBA Akebia Therapeutics	-$0.0360	N/A	N/A	N/A	$46.94 million	N/A
11/5/2026	Q3 2026	LXRX Lexicon Pharmaceuticals	-$0.06	N/A	N/A	N/A	$4.14 million	N/A
11/5/2026	Q3 2026	SANA Sana Biotechnology	-$0.1478	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
ANL Adlai Nortye	0.04	9.55	N/A
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ANL Adlai Nortye	35.21%
LXRX Lexicon Pharmaceuticals	74.70%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
ANL Adlai Nortye	N/A
LXRX Lexicon Pharmaceuticals	14.00%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	194	277.11 million	265.19 million	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
LXRX Lexicon Pharmaceuticals	81	444.96 million	382.66 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable

AKBA, ANL, SANA, and LXRX Headlines

Recent News About These Companies

Sana Biotechnology (NASDAQ:SANA) Sets New 1-Year Low - Here's What Happened

October 19, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.7% - What's Next?

October 13, 2026 | marketbeat.com

Sana Biotechnology: A Shot At Diabetes

October 13, 2026 | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low - Should You Sell?

October 12, 2026 | marketbeat.com

Sana Biotechnology, Inc. (SANA) - What Are Analysts Thinking About This Stock?

October 10, 2026 | marketbeat.com

Sana Biotechnology, Inc. Common Stock

October 9, 2026 | fxempire.comF

Sana Biotechnology (NASDAQ:SANA) Shares Up 3.1% - Here's Why

October 7, 2026 | marketbeat.com

Bank of America Corp DE Purchases New Holdings in Sana Biotechnology, Inc. $SANA

September 25, 2026 | marketbeat.com

6 'moonshot' biotech stocks that offer big risks, bigger rewards

September 23, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 7.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Sana Biotechnology (SANA)

September 23, 2026 | es.investing.com

Sana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

September 15, 2026 | seekingalpha.com

Sana Biotechnology op Morgan Stanley conferentie: focus op diabetes

September 15, 2026 | nl.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段

September 10, 2026 | cn.investing.com

Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法

September 10, 2026 | cn.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 7, 2026 | prnewswire.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1, 2026 | globenewswire.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AKBA, ANL, SANA, and LXRX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.58 +0.02 (+3.52%)

As of 12:53 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adlai Nortye NASDAQ:ANL

$10.48 -0.10 (-0.90%)

As of 12:53 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.42 -0.07 (-4.36%)

As of 12:53 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sana Biotechnology NASDAQ:SANA

$2.32 -0.06 (-2.32%)

As of 12:53 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, ANL, SANA, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, ANL, SANA, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, ANL, SANA, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AKBA, ANL, SANA, and LXRX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Adlai Nortye NASDAQ:ANL

Lexicon Pharmaceuticals NASDAQ:LXRX

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, ANL, SANA, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, ANL, SANA, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, ANL, SANA, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AKBA, ANL, SANA, and LXRX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Adlai Nortye NASDAQ:ANL

Lexicon Pharmaceuticals NASDAQ:LXRX

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools